Keywords: Actelion, Tracleer, Research, Pulmonary fibrosis,

Actelion shares plunge as Tracleer fails to meet primary endpoint in idiopathic pulmonary fibrosis

Article | 02 March 2010

Print This

Switzerland’s Actelion yesterday saw its shares plunge 16.2% to 45.90 Swiss francs, its lowest level for four years, after the company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in